

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Aquarius Surgical Technologies Inc. (the "Issuer").

Trading Symbol: ASTI

Number of Outstanding Listed Securities: 23,079,172

Date: September 7, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Salumatics Inc. continues to assist with the restructuring of administrative procedures, tightening of financial controls and the development of marketing programs for Surgical Lasers Inc. ("SLI"), our wholly owned subsidiary.

We are pleased to report sales are increasing in all three areas of revenue: outright purchases of laser units, enrollment in our \$0 CAPEX Placement Program, and fiber sales.

The year end audited statements and Q1 results have been released and we are looking to continue our forward direction. We are pleased with the reduced costs realized by our efforts and we are increasing our focus on both revenue and profit growth over the coming months.

2. Provide a general overview and discussion of the activities of management.

We are confident our efforts will reinforce our commitment to our current and future customers and sales force. This will allow us to grow together, weather the remainder of the pandemic, and emerge as a stronger more efficient organization, prepared for the future and exponential growth.

With the increased North American vaccination efforts we are starting to see increased procedures resulting in increased fiber sales, and are confident this trend can continue.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

See above

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None

8. Describe the acquisition of new customers or loss of customers.

None

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

The litigation against Gordon Willox and Christopher Schmid, their related "consultant" corporations, CAST Laser, Inc. and 1380511 Ontario Inc., their corporations used to fraudulently divert and misappropriate corporate assets, Surgical Lasers Solutions Corp.(Ontario), Surgical Lasers Solutions Corp. (Delaware), Surgical Laser Solutions Inc. and Clarity Medical Technologies Inc., and former consultants/employees Michael Szymanski and Sherry Geramikhosh, the commencement of which was reported in the Form 7 for July, 2021, is continuing. A Statement of Defence has been filed on behalf of all the defendants, and a counterclaim has been filed by Willox, CAST Laser, Inc., Schmid and 1380511 Ontario Inc. The litigation is now moving forward towards the Discovery process. It should be noted that litigation is, by its nature, of uncertain outcome, and recovery of any amount that may be ordered by a Judgment is dependent on the resources available to the defendants to meet any obligations.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
None			

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None

16. Provide details of any changes in directors, officers or committee members.

None

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Due to the outbreak of Covid-19 and corresponding social distancing initiatives, ASTI has had to re-schedule several demonstrations and evaluations at the request of hospitals. These represent qualified business opportunities and the corresponding demonstrations/evaluations will be rescheduled in the coming months as soon as the restrictions associated with the Covid-19 outbreak are removed. Regardless, ASTI's minimally invasive surgeries are still classified as essential procedures, specifically for patients who have issues associated with potential kidney failure or urinary retention. In this regard, the core business of ASTI will continue as it will be necessary for our existing clients to proceed with regularly scheduled surgeries for patients.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated September 7, 2021

N. Gary Van Nest
Name of Director or Senior Officer

Signed "Gary Van Nest"
Signature
CEO
Official Capacity

Issuer Details		For Month End	Date of Report
Name of Issuer Aquarius Surgical Technologies Inc.		August 2021	YY/MM/D 21/09/7
Issuer Address 89 Scollard Street			
City/Province/Postal Code Toronto, ON M5R 1G4		Issuer Fax No. (902)484-7599	Issuer Telephone No. (902) 496-7594
Contact Name Gary Van Nest		Contact Position CEO	Contact Telephone No (647) 308-0685.
Contact Email Address gary@sinaltainvestments.com		Web Site Address https://aquariussurgical.com	